FOLH1 and neoplasm: The mean absorbed kidney dose of [177Lu]Lu-PSMA-ALB-56 (2.55 ± 0.93 Gy/GBq) was about 3.3-fold higher than reported values for [177Lu]Lu-PSMA-617 (0.60–0.88 Gy/GBq) resulting in a tumor-to-kidney dose ratio of 3.3 ± 2.8 compared with a previously reported dose ratio of ~ 5.1 for [177Lu]Lu-PSMA-617 [37].